The Antimonopoly Office of the Slovak Republic approved concentration consisting in acquisition of exclusive indirect control by the undertaking GlaxoSmithKline plc. over the enterprise of the undertaking de Miclén a.s.

12.12.2013
On December 6, 2013 the Antimonopoly Office of the Slovak Republic Division of Concentrations approved concentration consisting in acquisition of exclusive indirect control by the undertaking GlaxoSmithKline plc., 980 Great West Road, Brenfort, Middlesex, TW8 9GS, United Kingdom (hereinafter only “GSK”) over the enterprise of the undertaking de Miclén a.s., nám. A. Hlinku 1, Bratislava (hereinafter only “de Miclén”).

GSK is a global company specializing in research, development, production, marketing and sale of vaccines, medicines and healthcare products. It also develops, produces and sells various brands of toothpaste. Part of the production of toothpastes is produces in its own plants and part is produced by several contractual producers. De Miclén is one of them.

Undertaking de Miclén is contractual producer of cosmetic and personal hygiene products for third parties. Main business activity of company de Miclén consists in production of toothpastes and hair cosmetics for other companies. De Miclén neither produces any products nor places them on the market under its own brand.

Since company de Miclén supplies the company GSK with toothpastes based on contractual production, the Office has been assessing the impacts of concentration both in the market of contractual production of toothpaste and in the market of production and sale of toothpastes.

It is highly improbable that after concentration the company GSK would be capable to prevent other contractual producers from the access to their customers. Therefore, the Office concluded that the subjected concentration would not result in significant infringement of efficient competition and it approved the concentration.

The decision came into force on 06. 12. 2013.
Last update:20.12.2013